06.10.2023 | Tracker

Product Launch Tracker: eHCPs had mixed opinions on the updated mRNA COVID-19 booster vaccines.

By Alexandra Maria Chatziioannidou

Every month, CREATION.co’s tracking updates bring you the latest insights from the online conversation of healthcare professionals (eHCPs) across the globe discussing product launches. Discover which new drug approvals eHCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout September 2023 CREATION.co tracked the global conversations of 1,555 eHCPs who posted 2,379 English-language X (formerly Twitter) posts about the launches and approvals of new products.

In September, fewer eHCPs discussed treatment approvals compared to the previous month and there were 14% less product launch mentions. eHCPs offered their thoughts on the approval of the new COVID-19 mRNA vaccine boosters as well as the approval of Jardiance for the treatment of chronic kidney disease.

On 11 September, the FDA granted full approval and authorisation for emergency use of the updated mRNA COVID-19 vaccines boosters, by Moderna and Pfizer, formulated to more closely target currently circulating variants. The reactions of eHCPs to the approval news were quite mixed. A number of eHCPs discussed, in their opinion, the lack of an emergency for such an approval, and raised concerns around the possible side effects on some population groups. On the other hand, many eHCPs recommended the booster vaccine, highlighting the severity of the disease and the importance of vaccinations to avoid hospitalisations.

On 22 September, the FDA announced the approval of Jardiance (empagliflozin) by Eli Lilly and Boehringer Ingelheim, an SGLT2 inhibitor, to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR) and hospitalisation in adults with chronic kidney disease (CKD). eHCPs did not express many opinions around the approval but they frequently shared the news of the approval online, often sharing the announcement of Boehringer Ingelheim. 


On 15 September, the FDA granted approval to GSK’s Ojjaara (momelotinib) for the treatment of patients with intermediate or high-risk myelofibrosis with anaemia. Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. eHCPs were deeply excited, as they quoted, about the approval having the potential to change the clinical practice. They mentioned that they are eager to have this fantastic news brought into practice in the UK and EU as well.

The three most shared stories from eHCPs discussing product launches in September were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language X conversations of eHCPs globally discussing new pharmaceutical product launches and drug approvals between 1 September and 30 September 2023 were analysed in order to discover which new product launches eHCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by eHCPs in their X conversations.
  • Between 1 September and 30 September 2023, there were 2,379 eHCP mentions of new pharmaceutical product launches and drug approvals from 1,555 unique eHCP authors from around the world. 



View all articles >

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!